Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 May 1;5(5):a021436.
doi: 10.1101/cshperspect.a021436.

Hepatitis B virus genotypes and variants

Chih-Lin Lin  1 , Jia-Horng Kao  2
Affiliations
Review

Hepatitis B virus genotypes and variants

Chih-Lin Lin et al. Cold Spring Harb Perspect Med. .

Abstract

At least 10 hepatitis B virus (HBV) genotypes (A to J) with distinct geographic distributions and several HBV mutants, including precore/core promoter mutations and pre-S/S deletion mutations, have been recognized to be not only predictive of liver disease progression but also associated with response to antiviral therapy. HBV genotype-specific pathogenesis may contribute to heterogeneous clinical outcomes in chronic hepatitis B patients across the world. For example, patients with HBV genotypes C and D infection have a lower rate of spontaneous HBeAg seroconversion. In addition, HBV genotypes C and D have a higher frequency of core promoter and pre-S mutations than genotypes A and B. Genotypes C and D also carry a higher lifetime risk of cirrhosis and HCC development than genotypes A and B. Core promoter and pre-S mutations also correlate with an increased risk of hepatocellular carcinoma (HCC). Therapeutically, genotypes A and B patients have a better response to interferon-based therapy than genotypes C and D patients, but the response to nucleos(t)ide analogs is comparable across different HBV genotypes. In conclusion, HBV genotypes and variants may serve as viral genetic markers to predict disease progression as well as help practicing physicians optimize individualized antiviral therapy in clinical practice.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The partially double-stranded circular DNA of hepatitis B virus encodes four overlapping open reading frames: S for the surface or envelope gene; C for the core gene; P for the polymerase gene; and X for the X gene. Naturally occurring mutant strains including mutations in precore, core promoter, and deletion mutation in pre-S genes have been reported to be associated with the pathogenesis of progressive liver disease and risk of hepatocellular carcinoma (HCC) development. (From Kao et al. 2010; adapted, with permission, Elsevier © 2010.)
Figure 2.
Figure 2.
Odds ratios of hepatocellular carcinoma for HBV carriers by mutations in core promoter and pre-S regions in a meta-analysis. (Imaged created from data in Liu et al. 2009b.)
Figure 3.
Figure 3.
Hypothetical algorithm for HBV genotype–specific antiviral treatment in patients with chronic hepatitis B.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Beck J, Nassal M. 2007. Hepatitis B virus replication. World J Gastroenterol 13: 48–64. - PMC - PubMed
    1. Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, Romagnoli V, Cherubini B, Moscato G, Maina AM, et al. 2010. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 139: 483–490. - PubMed
    1. Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, Rothe V, Regep L, Bonino F. 2013. Response to peginterferon α-2a (40 KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol 59: 1153–1159. - PubMed
    1. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, et al. 2008. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon α-2b. Gastroenterology 135: 459–467. - PubMed
    1. Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL. 2009. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-α. Gastroenterology 137: 2002–2009. - PubMed